GCTK vs. NRXS, NXGL, PETV, XAIR, IRIX, LFWD, ICU, INBS, BTCY, and VVOS
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include NeurAxis (NRXS), NEXGEL (NXGL), PetVivo (PETV), Beyond Air (XAIR), IRIDEX (IRIX), ReWalk Robotics (LFWD), SeaStar Medical (ICU), Intelligent Bio Solutions (INBS), Biotricity (BTCY), and Vivos Therapeutics (VVOS). These companies are all part of the "medical equipment" industry.
GlucoTrack vs. Its Competitors
GlucoTrack (NASDAQ:GCTK) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.
NeurAxis has a consensus price target of $7.00, indicating a potential upside of 195.36%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than GlucoTrack.
In the previous week, NeurAxis had 2 more articles in the media than GlucoTrack. MarketBeat recorded 3 mentions for NeurAxis and 1 mentions for GlucoTrack. NeurAxis' average media sentiment score of 0.99 beat GlucoTrack's score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.
GlucoTrack has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 12.9% of GlucoTrack shares are owned by company insiders. Comparatively, 26.4% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NeurAxis has higher revenue and earnings than GlucoTrack. NeurAxis is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
NeurAxis received 3 more outperform votes than GlucoTrack when rated by MarketBeat users. Likewise, 100.00% of users gave NeurAxis an outperform vote while only 0.00% of users gave GlucoTrack an outperform vote.
GlucoTrack has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.34, meaning that its stock price is 234% more volatile than the S&P 500.
Summary
NeurAxis beats GlucoTrack on 13 of the 16 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
This page (NASDAQ:GCTK) was last updated on 6/23/2025 by MarketBeat.com Staff
Buy GCTK Stock Free GCTK Stock Alerts